Eli Lilly and Company– tag –
-
Key FDA Approvals Anticipated for GLP-1 Pipeline in May 2026 Update
Prime Therapeutics - Portal USA Overview Four significant FDA approval decisions for GLP-1 related medications are expected in 2026, marking critical advancements in metabolic disease management. Eli Lilly's injectable Mounjaro is antici... -
Eli Lilly Seals Landmark $2.75 Billion AI Drug Discovery Alliance with Insilico Medicine
IntuitionLabs, TipRanks, Tech Funding News USA Overview Pharmaceutical giant Eli Lilly has forged a strategic drug discovery and development collaboration with AI biotech pioneer Insilico Medicine, valued at up to $2.75 billion. The deal... -
Beyond GLP-1: Next-Gen Obesity Drug Race Accelerates with Multi-Agonist Therapies
The Elec Inc. South Korea Overview The race for next-generation obesity drugs is expanding beyond GLP-1 injections into multi-agonist therapies targeting multiple hormones. Eli Lilly's Retatrutide, a triple agonist for GLP-1, GIP, and gl... -
Eli Lilly Acquires Engage Biologics for Up to $202 Million to Strengthen Non-Viral DNA Delivery Platform
GuruFocus USA Overview Eli Lilly has agreed to acquire Engage Biologics for up to $202 million, aiming to leverage Engage’s innovative non-viral DNA delivery platform and accelerate the development of next-generation gene therapies. Enga... -
Lilly’s Retatrutide Achieves Unprecedented Weight Loss in Pivotal Phase 3 Obesity Trial
Eli Lilly and Company USA Overview Eli Lilly's triple-agonist retatrutide, targeting GIP, GLP-1, and glucagon receptors, demonstrated powerful efficacy in its pivotal Phase 3 TRIUMPH-1 trial for obesity. Patients receiving the highest do... -
The In Vivo CAR-T Race Heats Up: Big Pharma Acquisitions and Astellas’ Strategic Collaborations Signal a New Era in Cancer Therapy
Answers（アンサーズ） Japan Overview The global race to develop 'in vivo CAR-T therapy,' which generates CAR-T cells directly within the patient's body, is intensely accelerating as major pharmaceutical companies invest heavily. This inn... -
South Korean Biotech Giants Diverge: Samsung Biologics Faces Labor Risks Amid Record Growth, Celltrion Boosts Global CDMO Expansion
aju press South Korea Overview South Korea's leading biotech firms, Samsung Biologics and Celltrion, show divergent paths: Samsung Biologics achieved record Q1 2026 performance with 25.8% revenue growth due to full plant utilization but ... -
Eli Lilly’s Oral Orforglipron Effective in Older Adults with Obesity, Receives FDA Approval as Non-Peptide GLP-1 Offering Dosing Flexibility
Medscape USA Overview Eli Lilly's once-daily oral GLP-1 receptor agonist, orforglipron (Foundayo), demonstrated clinically significant weight loss and a favorable safety profile in obese adults aged 65 and older, similar to younger popul... -
Novo Nordisk’s CagriSema Achieves Over 22% Weight Loss in Phase 3 Trials: Synergistic Benefits of GLP-1 and Amylin Analog
Life Science Daily News Global Overview Novo Nordisk's CagriSema, a combination therapy featuring a GLP-1 receptor agonist and the amylin analog cagrilintide, demonstrated over 22% weight reduction in Phase 3 trials. Specifically, the RE... -
GLP-1 Drug Manufacturing: Global Capacity Expansion and Tech Transfer Accelerate to Meet Soaring Demand
IntuitionLabs Global Overview The unprecedented surge in demand for GLP-1 therapeutics is driving a rapid global expansion of manufacturing capacity and technology transfer strategies in the pharmaceutical industry. Novo Nordisk is inves...
